nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP1A2—Carmustine—lymphatic system cancer	0.18	0.246	CbGbCtD
Nevirapine—CYP3A5—Teniposide—lymphatic system cancer	0.162	0.222	CbGbCtD
Nevirapine—CYP2C9—Teniposide—lymphatic system cancer	0.109	0.149	CbGbCtD
Nevirapine—CYP3A5—Vincristine—lymphatic system cancer	0.0782	0.107	CbGbCtD
Nevirapine—CYP3A4—Cytarabine—lymphatic system cancer	0.0643	0.0879	CbGbCtD
Nevirapine—CYP3A4—Teniposide—lymphatic system cancer	0.0634	0.0866	CbGbCtD
Nevirapine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0443	0.0605	CbGbCtD
Nevirapine—CYP3A4—Vincristine—lymphatic system cancer	0.0305	0.0417	CbGbCtD
Nevirapine—Neutropenia—Fludarabine—lymphatic system cancer	0.00183	0.00684	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00178	0.00665	CcSEcCtD
Nevirapine—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00177	0.0066	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00173	0.00646	CcSEcCtD
Nevirapine—Mouth ulceration—Vincristine—lymphatic system cancer	0.00173	0.00644	CcSEcCtD
Nevirapine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00172	0.00642	CcSEcCtD
Nevirapine—Renal failure—Fludarabine—lymphatic system cancer	0.00172	0.00641	CcSEcCtD
Nevirapine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00171	0.00639	CcSEcCtD
Nevirapine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00168	0.00628	CcSEcCtD
Nevirapine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00167	0.00623	CcSEcCtD
Nevirapine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00164	0.00612	CcSEcCtD
Nevirapine—Hepatic failure—Vincristine—lymphatic system cancer	0.00154	0.00575	CcSEcCtD
Nevirapine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0015	0.00558	CcSEcCtD
Nevirapine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00148	0.00553	CcSEcCtD
Nevirapine—Anaemia—Teniposide—lymphatic system cancer	0.00144	0.00536	CcSEcCtD
Nevirapine—Face oedema—Carmustine—lymphatic system cancer	0.0014	0.00523	CcSEcCtD
Nevirapine—Liver disorder—Methotrexate—lymphatic system cancer	0.00136	0.00507	CcSEcCtD
Nevirapine—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00134	0.005	CcSEcCtD
Nevirapine—Oedema—Teniposide—lymphatic system cancer	0.00127	0.00473	CcSEcCtD
Nevirapine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00127	0.00473	CcSEcCtD
Nevirapine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00127	0.00473	CcSEcCtD
Nevirapine—Anaemia—Fludarabine—lymphatic system cancer	0.00126	0.00471	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00125	0.00465	CcSEcCtD
Nevirapine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00124	0.00463	CcSEcCtD
Nevirapine—Malaise—Fludarabine—lymphatic system cancer	0.00123	0.00459	CcSEcCtD
Nevirapine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00122	0.00454	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00122	0.00453	CcSEcCtD
Nevirapine—Anorexia—Teniposide—lymphatic system cancer	0.00121	0.00451	CcSEcCtD
Nevirapine—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.0012	0.00447	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00119	0.00444	CcSEcCtD
Nevirapine—Necrosis—Methotrexate—lymphatic system cancer	0.00118	0.0044	CcSEcCtD
Nevirapine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00118	0.00439	CcSEcCtD
Nevirapine—Neutropenia—Carmustine—lymphatic system cancer	0.00117	0.00438	CcSEcCtD
Nevirapine—Myalgia—Fludarabine—lymphatic system cancer	0.00116	0.00434	CcSEcCtD
Nevirapine—Arthralgia—Fludarabine—lymphatic system cancer	0.00116	0.00434	CcSEcCtD
Nevirapine—Discomfort—Fludarabine—lymphatic system cancer	0.00115	0.00429	CcSEcCtD
Nevirapine—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00113	0.00422	CcSEcCtD
Nevirapine—Neutropenia—Vincristine—lymphatic system cancer	0.00112	0.00418	CcSEcCtD
Nevirapine—Oedema—Fludarabine—lymphatic system cancer	0.00111	0.00416	CcSEcCtD
Nevirapine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00111	0.00416	CcSEcCtD
Nevirapine—Decreased appetite—Teniposide—lymphatic system cancer	0.0011	0.00411	CcSEcCtD
Nevirapine—Renal failure—Carmustine—lymphatic system cancer	0.0011	0.0041	CcSEcCtD
Nevirapine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.0011	0.00409	CcSEcCtD
Nevirapine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00109	0.00408	CcSEcCtD
Nevirapine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00109	0.00408	CcSEcCtD
Nevirapine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00109	0.00407	CcSEcCtD
Nevirapine—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00109	0.00407	CcSEcCtD
Nevirapine—Rash—Mechlorethamine—lymphatic system cancer	0.00108	0.00405	CcSEcCtD
Nevirapine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00108	0.00404	CcSEcCtD
Nevirapine—Anorexia—Fludarabine—lymphatic system cancer	0.00106	0.00396	CcSEcCtD
Nevirapine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00105	0.00392	CcSEcCtD
Nevirapine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00105	0.0039	CcSEcCtD
Nevirapine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00105	0.0039	CcSEcCtD
Nevirapine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00104	0.00387	CcSEcCtD
Nevirapine—Bone disorder—Methotrexate—lymphatic system cancer	0.00103	0.00383	CcSEcCtD
Nevirapine—Renal failure—Mitoxantrone—lymphatic system cancer	0.00102	0.00381	CcSEcCtD
Nevirapine—Nausea—Mechlorethamine—lymphatic system cancer	0.00102	0.00381	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00102	0.00379	CcSEcCtD
Nevirapine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00101	0.00378	CcSEcCtD
Nevirapine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00101	0.00377	CcSEcCtD
Nevirapine—Urticaria—Teniposide—lymphatic system cancer	0.00101	0.00376	CcSEcCtD
Nevirapine—Abdominal pain—Teniposide—lymphatic system cancer	0.001	0.00374	CcSEcCtD
Nevirapine—Body temperature increased—Teniposide—lymphatic system cancer	0.001	0.00374	CcSEcCtD
Nevirapine—Erythema—Bleomycin—lymphatic system cancer	0.001	0.00374	CcSEcCtD
Nevirapine—Paraesthesia—Fludarabine—lymphatic system cancer	0.001	0.00373	CcSEcCtD
Nevirapine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000987	0.00368	CcSEcCtD
Nevirapine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000979	0.00365	CcSEcCtD
Nevirapine—Ulcer—Methotrexate—lymphatic system cancer	0.000979	0.00365	CcSEcCtD
Nevirapine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00097	0.00362	CcSEcCtD
Nevirapine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000969	0.00361	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000962	0.00359	CcSEcCtD
Nevirapine—Fatigue—Fludarabine—lymphatic system cancer	0.000961	0.00359	CcSEcCtD
Nevirapine—Inflammation—Methotrexate—lymphatic system cancer	0.000955	0.00356	CcSEcCtD
Nevirapine—Pain—Fludarabine—lymphatic system cancer	0.000953	0.00356	CcSEcCtD
Nevirapine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000942	0.00351	CcSEcCtD
Nevirapine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000934	0.00349	CcSEcCtD
Nevirapine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000934	0.00348	CcSEcCtD
Nevirapine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000929	0.00347	CcSEcCtD
Nevirapine—Anaemia—Bleomycin—lymphatic system cancer	0.000926	0.00345	CcSEcCtD
Nevirapine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000919	0.00343	CcSEcCtD
Nevirapine—Asthenia—Teniposide—lymphatic system cancer	0.00091	0.00339	CcSEcCtD
Nevirapine—Malaise—Bleomycin—lymphatic system cancer	0.000903	0.00337	CcSEcCtD
Nevirapine—Pruritus—Teniposide—lymphatic system cancer	0.000897	0.00335	CcSEcCtD
Nevirapine—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000884	0.0033	CcSEcCtD
Nevirapine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000881	0.00329	CcSEcCtD
Nevirapine—Erythema—Carmustine—lymphatic system cancer	0.000874	0.00326	CcSEcCtD
Nevirapine—Diarrhoea—Teniposide—lymphatic system cancer	0.000868	0.00324	CcSEcCtD
Nevirapine—Myalgia—Bleomycin—lymphatic system cancer	0.000853	0.00318	CcSEcCtD
Nevirapine—Discomfort—Bleomycin—lymphatic system cancer	0.000842	0.00314	CcSEcCtD
Nevirapine—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000837	0.00312	CcSEcCtD
Nevirapine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000821	0.00306	CcSEcCtD
Nevirapine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000817	0.00305	CcSEcCtD
Nevirapine—Oedema—Bleomycin—lymphatic system cancer	0.000817	0.00305	CcSEcCtD
Nevirapine—Erythema—Mitoxantrone—lymphatic system cancer	0.000813	0.00303	CcSEcCtD
Nevirapine—Anaemia—Carmustine—lymphatic system cancer	0.000808	0.00301	CcSEcCtD
Nevirapine—Vomiting—Teniposide—lymphatic system cancer	0.000806	0.00301	CcSEcCtD
Nevirapine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0008	0.00299	CcSEcCtD
Nevirapine—Asthenia—Fludarabine—lymphatic system cancer	0.0008	0.00298	CcSEcCtD
Nevirapine—Rash—Teniposide—lymphatic system cancer	0.0008	0.00298	CcSEcCtD
Nevirapine—Dermatitis—Teniposide—lymphatic system cancer	0.000799	0.00298	CcSEcCtD
Nevirapine—Headache—Teniposide—lymphatic system cancer	0.000795	0.00296	CcSEcCtD
Nevirapine—Pruritus—Fludarabine—lymphatic system cancer	0.000789	0.00294	CcSEcCtD
Nevirapine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000788	0.00294	CcSEcCtD
Nevirapine—Anorexia—Bleomycin—lymphatic system cancer	0.000779	0.00291	CcSEcCtD
Nevirapine—Anaemia—Vincristine—lymphatic system cancer	0.000771	0.00288	CcSEcCtD
Nevirapine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000763	0.00285	CcSEcCtD
Nevirapine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000754	0.00281	CcSEcCtD
Nevirapine—Nausea—Teniposide—lymphatic system cancer	0.000753	0.00281	CcSEcCtD
Nevirapine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000751	0.0028	CcSEcCtD
Nevirapine—Hepatic failure—Methotrexate—lymphatic system cancer	0.000748	0.00279	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000745	0.00278	CcSEcCtD
Nevirapine—Myalgia—Carmustine—lymphatic system cancer	0.000744	0.00278	CcSEcCtD
Nevirapine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000734	0.00274	CcSEcCtD
Nevirapine—Malaise—Mitoxantrone—lymphatic system cancer	0.000733	0.00273	CcSEcCtD
Nevirapine—Oedema—Carmustine—lymphatic system cancer	0.000713	0.00266	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000713	0.00266	CcSEcCtD
Nevirapine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00071	0.00265	CcSEcCtD
Nevirapine—Myalgia—Vincristine—lymphatic system cancer	0.00071	0.00265	CcSEcCtD
Nevirapine—Vomiting—Fludarabine—lymphatic system cancer	0.000709	0.00264	CcSEcCtD
Nevirapine—Rash—Fludarabine—lymphatic system cancer	0.000703	0.00262	CcSEcCtD
Nevirapine—Dermatitis—Fludarabine—lymphatic system cancer	0.000702	0.00262	CcSEcCtD
Nevirapine—Pain—Bleomycin—lymphatic system cancer	0.000699	0.00261	CcSEcCtD
Nevirapine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000698	0.00261	CcSEcCtD
Nevirapine—Headache—Fludarabine—lymphatic system cancer	0.000698	0.00261	CcSEcCtD
Nevirapine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000692	0.00258	CcSEcCtD
Nevirapine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000692	0.00258	CcSEcCtD
Nevirapine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000684	0.00255	CcSEcCtD
Nevirapine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000681	0.00254	CcSEcCtD
Nevirapine—Oedema—Vincristine—lymphatic system cancer	0.000681	0.00254	CcSEcCtD
Nevirapine—Anorexia—Carmustine—lymphatic system cancer	0.00068	0.00254	CcSEcCtD
Nevirapine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000673	0.00251	CcSEcCtD
Nevirapine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000668	0.00249	CcSEcCtD
Nevirapine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000667	0.00249	CcSEcCtD
Nevirapine—Oedema—Mitoxantrone—lymphatic system cancer	0.000663	0.00247	CcSEcCtD
Nevirapine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000663	0.00247	CcSEcCtD
Nevirapine—Nausea—Fludarabine—lymphatic system cancer	0.000662	0.00247	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00065	0.00242	CcSEcCtD
Nevirapine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000649	0.00242	CcSEcCtD
Nevirapine—Urticaria—Bleomycin—lymphatic system cancer	0.000649	0.00242	CcSEcCtD
Nevirapine—Anorexia—Vincristine—lymphatic system cancer	0.000649	0.00242	CcSEcCtD
Nevirapine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000646	0.00241	CcSEcCtD
Nevirapine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000644	0.0024	CcSEcCtD
Nevirapine—Paraesthesia—Carmustine—lymphatic system cancer	0.000641	0.00239	CcSEcCtD
Nevirapine—Somnolence—Carmustine—lymphatic system cancer	0.000634	0.00237	CcSEcCtD
Nevirapine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000632	0.00236	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000621	0.00232	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00062	0.00231	CcSEcCtD
Nevirapine—Decreased appetite—Carmustine—lymphatic system cancer	0.00062	0.00231	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000616	0.0023	CcSEcCtD
Nevirapine—Paraesthesia—Vincristine—lymphatic system cancer	0.000612	0.00228	CcSEcCtD
Nevirapine—Pain—Carmustine—lymphatic system cancer	0.00061	0.00228	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000605	0.00226	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000604	0.00225	CcSEcCtD
Nevirapine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000602	0.00225	CcSEcCtD
Nevirapine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000596	0.00222	CcSEcCtD
Nevirapine—Decreased appetite—Vincristine—lymphatic system cancer	0.000592	0.00221	CcSEcCtD
Nevirapine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00059	0.0022	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000588	0.00219	CcSEcCtD
Nevirapine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000588	0.00219	CcSEcCtD
Nevirapine—Fatigue—Vincristine—lymphatic system cancer	0.000587	0.00219	CcSEcCtD
Nevirapine—Asthenia—Bleomycin—lymphatic system cancer	0.000586	0.00219	CcSEcCtD
Nevirapine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000583	0.00218	CcSEcCtD
Nevirapine—Pain—Vincristine—lymphatic system cancer	0.000582	0.00217	CcSEcCtD
Nevirapine—Pruritus—Bleomycin—lymphatic system cancer	0.000578	0.00216	CcSEcCtD
Nevirapine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000577	0.00215	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000575	0.00215	CcSEcCtD
Nevirapine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000572	0.00213	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—lymphatic system cancer	0.00057	0.00213	CcSEcCtD
Nevirapine—Pain—Mitoxantrone—lymphatic system cancer	0.000567	0.00212	CcSEcCtD
Nevirapine—Abdominal pain—Carmustine—lymphatic system cancer	0.000564	0.0021	CcSEcCtD
Nevirapine—Body temperature increased—Carmustine—lymphatic system cancer	0.000564	0.0021	CcSEcCtD
Nevirapine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000557	0.00208	CcSEcCtD
Nevirapine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000547	0.00204	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—lymphatic system cancer	0.000543	0.00203	CcSEcCtD
Nevirapine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000542	0.00202	CcSEcCtD
Nevirapine—Abdominal pain—Vincristine—lymphatic system cancer	0.000538	0.00201	CcSEcCtD
Nevirapine—Body temperature increased—Vincristine—lymphatic system cancer	0.000538	0.00201	CcSEcCtD
Nevirapine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000527	0.00197	CcSEcCtD
Nevirapine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000526	0.00196	CcSEcCtD
Nevirapine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000524	0.00196	CcSEcCtD
Nevirapine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000524	0.00196	CcSEcCtD
Nevirapine—Vomiting—Bleomycin—lymphatic system cancer	0.00052	0.00194	CcSEcCtD
Nevirapine—Rash—Bleomycin—lymphatic system cancer	0.000515	0.00192	CcSEcCtD
Nevirapine—Dermatitis—Bleomycin—lymphatic system cancer	0.000515	0.00192	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000514	0.00192	CcSEcCtD
Nevirapine—Asthenia—Carmustine—lymphatic system cancer	0.000512	0.00191	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—lymphatic system cancer	0.000509	0.0019	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000504	0.00188	CcSEcCtD
Nevirapine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000502	0.00187	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00049	0.00183	CcSEcCtD
Nevirapine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000489	0.00182	CcSEcCtD
Nevirapine—Asthenia—Vincristine—lymphatic system cancer	0.000489	0.00182	CcSEcCtD
Nevirapine—Diarrhoea—Carmustine—lymphatic system cancer	0.000488	0.00182	CcSEcCtD
Nevirapine—Nausea—Bleomycin—lymphatic system cancer	0.000485	0.00181	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000483	0.0018	CcSEcCtD
Nevirapine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000476	0.00178	CcSEcCtD
Nevirapine—Diarrhoea—Vincristine—lymphatic system cancer	0.000466	0.00174	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—lymphatic system cancer	0.000465	0.00174	CcSEcCtD
Nevirapine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000454	0.00169	CcSEcCtD
Nevirapine—Vomiting—Carmustine—lymphatic system cancer	0.000454	0.00169	CcSEcCtD
Nevirapine—Rash—Carmustine—lymphatic system cancer	0.00045	0.00168	CcSEcCtD
Nevirapine—Dermatitis—Carmustine—lymphatic system cancer	0.000449	0.00168	CcSEcCtD
Nevirapine—Headache—Carmustine—lymphatic system cancer	0.000447	0.00167	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00044	0.00164	CcSEcCtD
Nevirapine—Vomiting—Vincristine—lymphatic system cancer	0.000433	0.00162	CcSEcCtD
Nevirapine—Rash—Vincristine—lymphatic system cancer	0.000429	0.0016	CcSEcCtD
Nevirapine—Dermatitis—Vincristine—lymphatic system cancer	0.000429	0.0016	CcSEcCtD
Nevirapine—Headache—Vincristine—lymphatic system cancer	0.000427	0.00159	CcSEcCtD
Nevirapine—Nausea—Carmustine—lymphatic system cancer	0.000424	0.00158	CcSEcCtD
Nevirapine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000422	0.00157	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00042	0.00157	CcSEcCtD
Nevirapine—Rash—Mitoxantrone—lymphatic system cancer	0.000418	0.00156	CcSEcCtD
Nevirapine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000418	0.00156	CcSEcCtD
Nevirapine—Headache—Mitoxantrone—lymphatic system cancer	0.000415	0.00155	CcSEcCtD
Nevirapine—Erythema—Methotrexate—lymphatic system cancer	0.000405	0.00151	CcSEcCtD
Nevirapine—Nausea—Vincristine—lymphatic system cancer	0.000405	0.00151	CcSEcCtD
Nevirapine—Nausea—Mitoxantrone—lymphatic system cancer	0.000394	0.00147	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000376	0.0014	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—lymphatic system cancer	0.000374	0.0014	CcSEcCtD
Nevirapine—Malaise—Methotrexate—lymphatic system cancer	0.000365	0.00136	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—lymphatic system cancer	0.000345	0.00129	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—lymphatic system cancer	0.000345	0.00129	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000342	0.00128	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—lymphatic system cancer	0.000341	0.00127	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00033	0.00123	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000324	0.00121	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000324	0.00121	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—lymphatic system cancer	0.000321	0.0012	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—lymphatic system cancer	0.000315	0.00118	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000301	0.00112	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000297	0.00111	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—lymphatic system cancer	0.000294	0.0011	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000287	0.00107	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000285	0.00106	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—lymphatic system cancer	0.000285	0.00106	CcSEcCtD
Nevirapine—Pain—Methotrexate—lymphatic system cancer	0.000283	0.00105	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000272	0.00102	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00027	0.00101	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—lymphatic system cancer	0.000263	0.000979	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000261	0.000975	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000261	0.000975	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000243	0.000908	CcSEcCtD
Nevirapine—Asthenia—Methotrexate—lymphatic system cancer	0.000237	0.000884	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—lymphatic system cancer	0.000234	0.000872	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000226	0.000843	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—lymphatic system cancer	0.00021	0.000784	CcSEcCtD
Nevirapine—Rash—Methotrexate—lymphatic system cancer	0.000208	0.000777	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—lymphatic system cancer	0.000208	0.000777	CcSEcCtD
Nevirapine—Headache—Methotrexate—lymphatic system cancer	0.000207	0.000772	CcSEcCtD
Nevirapine—Nausea—Methotrexate—lymphatic system cancer	0.000196	0.000732	CcSEcCtD
